5 days ago
3
Skip to navigation Skip to main contented Skip to close file
TipRanks
Tue, January 13, 2026 astatine 6:27 AM CST 1 min read
Agios Pharmaceuticals (AGIO) announced its 2026 strategical priorities and cardinal milestones anticipated during the year. Key highlights: AQVESME U.S. commercialized motorboat successful thalassemia underway pursuing December 2025 FDA approval; Pre-sNDA gathering with FDA for mitapivat successful sickle compartment illness anticipated successful archetypal 4th of 2026, with planned U.S. regulatory submission to follow; Company progressing early- and mid-stage pipeline successful aggregate high-value indications; way to profitability done the company’s existing commercialized beingness successful thalassemia and PK deficiency, with imaginable to execute implicit $1 cardinal successful highest planetary sales
-
Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
-
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See today’s best-performing stocks connected TipRanks >>
Read More connected AGIO:
Disclaimer & DisclosureReport an Issue
-
Agios Pharmaceuticals terms people raised to $35 from $34 astatine BofA
-
Agios Pharmaceuticals terms people raised to $25 from $20 astatine JPMorgan
-
Agios Pharma: Broad Aqvesme Label, Premium Pricing, and Manageable Safety Profile Support Buy Rating and 54.5% Upside Potential
-
Agios Pharmaceuticals: Thalassemia Approval, Premium Pricing, and Manageable REMS Drive Higher Target and Undervalued Buy Thesis
-
Agios: FDA Approval of Aqvesme successful Thalassemia Unlocks Transformational Market Opportunity, Supporting Buy Rating and Higher Target
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·